Clinical Trial Update: ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating the combination of ASTX727, venetoclax, and gilteritinib for newly diagnosed, relapsed or refractory FLT3-mutated ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Gilteritinib (gilteritinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: RECRUITING